AGS Health(R) CEO Patrice Wolfe Named one of the Becker's Healthcare 'Top Women to Know in Health IT'
WASHINGTON, DC / ACCESS Newswire AGS Health ® CEO Patrice Wolfe has been named to the Becker's Hospital Review list of 'Women in Health IT to Know' in 2025. The annual list recognizes women who are harnessing the power of health IT to help shape the future of the healthcare industry.
Wolfe has been at the helm of AGS Health, a leading provider of tech-enabled revenue cycle management (RCM) solutions and a strategic growth partner to healthcare providers across the U.S., for nearly six years. During her tenure, the company has evolved into a market leader in technology-led RCM solutions, strengthening its capabilities through strategic acquisitions and the organic development of proprietary technologies.
Central to Wolfe's leadership is a bold vision for a frictionless revenue cycle powered by a hybrid intelligence model that seamlessly blends human expertise with the speed, scale, and precision of artificial intelligence (AI). This model enhances human decision-making with AI's analytical power, creating a synergistic system designed to prioritize outcomes over narrowly defined metrics and point solutions.
'Healthcare leaders are seeking a more strategic approach to revenue cycle management-one that goes beyond transactional efficiency and focuses on delivering measurable financial and clinical outcomes,' said Wolfe. 'That's the philosophy behind our hybrid intelligence model. Our clients view us not merely as a vendor but as a long-term strategic partner. The success of our solutions is measured by the tangible impact we deliver, whether that's increasing cash flow, reducing denials, or improving the patient financial experience.'
Under Wolfe's leadership, AGS Health has introduced a series of transformative advancements aimed at modernizing and optimizing revenue cycle operations. Key innovations include the deployment of agentic automation, autonomous medical coding solutions, and hybrid intelligence solutions for front-end financial clearance and prior authorization processes. The company has also developed proprietary workflow orchestration tools that enhance the efficiency, accuracy, and decision-making capabilities of its service teams through intelligent automation and real-time data insights.
Wolfe also spearheaded the company's geographic expansion into Mexico and the Philippines, broadening customers' access to diverse, highly skilled talent pools that are uniquely suited for clinical administrative support roles.
In recognition of its strong workplace culture and employee engagement, AGS Health earned Great Place to Work ® certification in India, the United States, and the Philippines. The company also achieved significant industry recognition, including being named a Leader in Everest Group's Medical Coding Operations PEAK Matrix ® Assessment and receiving four consecutive Leader and Star Performer designations in Everest Group's RCM Operations evaluations.
Additional accolades under Wolfe's tenure include being named 'Most Improved Services Solution – Best in KLAS: Software & Services,' earning the KLAS Research and Censinet Cybersecurity Transparent designation, and receiving the UiPath AI25 Award along with the Data Security Council of India (DSCI) Excellence Award for Best Security Practices in an Organization.
'I am honored to be among such an elite group of women who are reshaping the healthcare industry,' says Wolfe. 'But I did not achieve this honor alone; credit extends to the exceptional AGS Health team, which shares my commitment to leveraging the latest technologies to deliver exceptional quality to our healthcare customers.'
The women leaders recognized on Becker's list, curated by the editorial team from nominations submitted across the healthcare ecosystem, utilize technology to drive meaningful change by streamlining administrative processes, enhancing care delivery, standardizing workflows, and elevating overall system efficiency. In its announcement, Becker's Healthcare stated its pride in honoring trailblazing women in health IT for their unwavering commitment to improving healthcare, adding that their leadership and innovation are essential to the continued success of their organizations and the healthcare industry.
The complete list of Women in Health IT to Know can be accessed here.
About AGS Health
AGS Health is more than a revenue cycle management company-we're a strategic partner for growth. Our distinctive methodology blends award-winning services with intelligent automation and high-touch customer support to deliver peak end-to-end revenue cycle performance and an empowering patient financial experience.
We employ a team of 15,000 highly trained and college-educated RCM experts who directly support more than 150 customers spanning a variety of care settings and specialties, including nearly 50% of the 20 most prominent U.S. hospitals and 40% of the nation's 10 largest health systems. Our thoughtfully crafted RCM solutions deliver measurable revenue growth and retention, enabling customers to achieve the revenue to realize their vision.
# # #
Media Contact:
Liz Goar
NPC Creative Services
liz@npccs.com
SOURCE: AGS Health
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
3 hours ago
- Associated Press
Does Hospital Indemnity Insurance Help Cover Recurring Stays?
NEW YORK, NY / ACCESS Newswire / June 21, 2025 / A three-day stay in the hospital costs an average of $30,000 in the United States.1 While health insurance can help reduce your out-of-pocket costs if you have to be admitted to the hospital, there are contingent costs that may not be covered by your insurer. The cost of hospital stays, and other expenses like childcare could have a significant impact while you are unable to work. A hospital indemnity insurance policy can help with these costs. Here, we explore what health insurance helps cover and how the cash benefits of hospital indemnity insurance can help fill coverage gaps relating to recurring hospital stays. What does health insurance help cover? Many people receive health insurance through their employer, which can help with the cost of a hospital stay. Employer-sponsored health insurance plans cost an average of $111 per month, while Marketplace plans cost an average of $456 per month.2 So, if you're wondering, " How much is health insurance ?,' the answer depends on your specific circumstances and plan options. Marketplace health insurance plans typically cover a range of essential health benefits, including:3 Outpatient services Emergency services Hospitalization for surgery or overnight stays Pregnancy, maternity and newborn care Mental health and behavioral health treatment Prescription drugs Rehabilitative and habilitative services and devices Laboratory services Preventive and wellness services Chronic disease management Pediatric services Hospital costs are usually covered at least in part by primary health insurance plans, but you'll still have to pay copays and deductibles, and your health insurance plan may be subject to coverage limits. What is hospital indemnity insurance? Hospital indemnity insurance is a supplemental plan that can help fill gaps in your primary health insurance. It's not a replacement for health insurance but can help you with unexpected expenses and provide additional support if you've had multiple hospital stays that forced you to reach a coverage limit. Hospital indemnity insurance works similarly to health insurance in that you pay premiums to an insurance provider in exchange for coverage. You may have access to a plan through your employer, or you can purchase an individual plan directly from an insurance company. Unlike health insurance, however, hospital indemnity insurance plans typically pay eligible cash benefits based on the policy option you choose. You can use the benefits in any way you see fit, such as: Out-of-pocket medical expenses Childcare Living expenses like groceries, rent and utilities Plans may function differently between providers, but typically, you can file a claim for care provided while in the hospital, and your insurance provider pays eligible claims to help you with the costs of your hospital stay. Why is hospital indemnity insurance worth it? There are a number of reasons why you might consider a hospital indemnity insurance plan. These may include: Added financial assistance: Hospital stays can be expensive, especially if you have to go multiple times in the same year. Hospital indemnity insurance helps provide added financial support for recurring visits. Flexibility: Health insurance plans typically pay the hospital directly for treatment. But hospital indemnity insurance pays cash benefits direct to the policyholder, unless otherwise assigned, so you can use it for both medical and non-medical costs. Surpassing coverage limits: If you've reached a health insurance coverage limit after being admitted to the hospital several times, you could still use the hospital indemnity insurance. Ultimately, if you think you or a family member will have multiple stays at the hospital in a given year, hospital indemnity insurance could help provide some added peace of mind. The bottom line Hospital indemnity insurance provides coverage options that can help with recurring hospital stays. This supplemental policy pays cash benefits direct to the policyholder, unless otherwise assigned, so you can use your benefits to help fill gaps in your health insurance coverage or help pay living expenses. Consider applying for a hospital indemnity insurance policy for added peace of mind. Sources: 1 - Why health insurance is important. Accessed May 12, 2025. 2 Ramsey Solutions - How Much Does Health Insurance Cost? Updated May 12, 2025. Accessed May 12, 2025. 3 - Health benefits & coverage. Accessed May 12, 2025. Content within this article is provided for general informational purposes and is not provided as tax, legal, health, or financial advice for any person or for any specific situation. Employers, employees, and other individuals should contact their own advisers about their situations. For complete details, including availability and costs of Aflac insurance, please contact your local Aflac agent. Aflac coverage is underwritten by American Family Life Assurance Company of Columbus. In New York, Aflac coverage is underwritten by American Family Life Assurance Company of New York. Hospital, B40000 series: In Delaware, Policies B40100DE & B4010HDE. In Idaho, Policies B40100ID & B4010HID. In Oklahoma, Policies B40100OK & B4010HOK. In Pennsylvania, Policies B40100PA & B4010HPA. In Virginia, Policies B40100VA & B4010HVA. Coverage may not be available in all states, including but not limited to DE, ID, NJ, NM, NY, VA or VT. Benefits/premium rates may vary based on state and plan levels. Optional riders may be available at an additional cost. Policies and riders may also contain a waiting period. Refer to the exact policy and rider forms for benefit details, definitions, limitations, and exclusions. Aflac WWHQ | 1932 Wynnton Road | Columbus, GA 31999 CONTACT: Senior PR & Corporate Communications Contact: Angie Blackmar, 706-392-2097 or [email protected] SOURCE: Aflac press release
Yahoo
13 hours ago
- Yahoo
Is Everest Group Stock Underperforming the Dow?
With a market cap of $14.2 billion, Everest Group, Ltd. (EG) is a global provider of reinsurance and insurance solutions through its Insurance and Reinsurance segments. The company offers a broad range of property and casualty products, including treaty and facultative reinsurance, as well as specialty lines such as catastrophe, marine, aviation, and mortgage reinsurance. Companies worth more than $10 billion are generally labeled as 'large-cap' stocks and Everest Group fits this criterion perfectly. The company operates across the United States, Europe, and internationally, serving clients through brokers and direct channels. 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio Warren Buffett Famously Warned to 'Make Money While You Sleep' or 'You Will Work Until You Die': 5 Stocks To Invest Like Buffett Unusually Active Put Options Signal Long Straddle Opportunity After Zoetis Downgrade Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Shares of the Hamilton, Bermuda-based company have declined 18.3% from its 52-week high of $407.30. Over the past three months, its shares have decreased 7.4%, underperforming the broader Dow Jones Industrials Average's ($DOWI) 1.4% rise during the same period. Longer term, EG stock is down 8.2% on a YTD basis, a steeper drop than DOWI's marginal decline. Moreover, shares of Everest Group have dipped 11.8% over the past 52 weeks, compared to DOWI's 8.6% increase over the same time frame. Despite a few fluctuations, the stock has been trading below its 50-day and 200-day moving averages since late October last year. Shares of Everest Group tumbled nearly 6% following its Q1 2025 results on Apr. 30 due to a steep 71% drop in net income to $210 million ($4.90 per share). The company posted a significant pre-tax catastrophe loss of $472 million, primarily due to California wildfires, which contributed to a deteriorated combined ratio of 102.7%. Both adjusted EPS of $6.45 and revenue of $4.3 billion missed Wall Street expectations. EG stock has performed weaker than its rival, SiriusPoint Ltd. (SPNT). SPNT stock has returned 17.9% YTD and 53.6% over the past 52 weeks. Despite the stock's underperformance, analysts remain moderately optimistic about its prospects. The stock has a consensus rating of 'Moderate Buy' from 13 analysts in coverage, and as of writing, EG is trading below the mean price target of $391.75. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Business Upturn
a day ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
